Translate Bio: France's Sanofi Expands MRNA Drive With US Firm Purchase

France's pharmaceutical giant Sanofi, which has lagged behind rivals in developing new generation mRNA Covid-19 vaccines, on Tuesday said it has purchased a US firm specialising in the technology. Sanofi will buy Translate Bio, with which it has been working to develop an mRNA Covid jab, for $3.2 billion (2.7 billion euros), the company said in a statement. Sanofi was left trailing in the race to break out a Covid-19 vaccine in 2020, as rivals Pfizer-BioNTech and Moderna used pioneering mRNA technology to develop jabs in record time.